Evidence map›Paper›PMID 20825283›Full record

ReviewHuman gene therapy2010

Genetic engineering of mesenchymal stem cells and its application in human disease therapy.

Conrad P Hodgkinson, José A Gomez, Maria Mirotsou, Victor J Dzau

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human gene therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Applications of synthetic biology in medical and pharmaceutical fields.Signal transduction and targeted therapy · 2023
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Conrad P HodgkinsonDepartment of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
José A Gomez
Maria Mirotsou
Victor J Dzau

Funding

GENE THERAPY FOR LONG-TERM MYOCARDIAL PROTECTIONR01HL072010 · NHLBI · DUKE UNIVERSITY · PI DZAU, VICTOR J · 2003 to 2013
$4.5M
Sfrp2 as a Stem Cell Derived Paracrine Factor for CardioprotectionR01HL081744 · NHLBI · DUKE UNIVERSITY · PI DZAU, VICTOR J · 2006 to 2015
$3.8M
RENIN GENE EXPRESSION IN HYPERTENSIONR01HL035610 · NHLBI · STANFORD UNIVERSITY · PI DZAU, VICTOR J · 1985 to 2011
$3.6M
Homing and Genetic Modification of Mesenchymal Stem CellR01HL073219 · NHLBI · DUKE UNIVERSITY · PI DZAU, VICTOR J · 2003 to 2012
$3.5M
NHLBI NIH HHS HL72010NHLBI NIH HHS HL73219NHLBI NIH HHS HL81744NHLBI NIH HHS R01 HL35610
6 · The paper itself

Abstract

The use of stem cells for tissue regeneration and repair is advancing both at the bench and bedside. Stem cells isolated from bone marrow are currently being tested for their therapeutic potential in a variety of clinical conditions including cardiovascular injury, kidney failure, cancer, and neurological and bone disorders. Despite the advantages, stem cell therapy is still limited by low survival, engraftment, and homing to damage area as well as inefficiencies in differentiating into fully functional tissues. Genetic engineering of mesenchymal stem cells is being explored as a means to circumvent some of these problems. This review presents the current understanding of the use of genetically engineered mesenchymal stem cells in human disease therapy with emphasis on genetic modifications aimed to improve survival, homing, angiogenesis, and heart function after myocardial infarction. Advancements in other disease areas are also discussed.

Indexed as

Mesenchymal Stem Cell TransplantationBone Marrow TransplantationCardiovascular DiseasesCell DifferentiationClinical Trials as TopicGenetic EngineeringHumansMesenchymal Stem CellsNeoplasmsNervous System DiseasesOsteogenesisRenal Insufficiency

Identifiers

PMID20825283
PMCPMC2978545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.